A huge number of Medtronic implantable defibrillators and their in-office programming devices and bedside monitors are vulnerable to hackers, the Department of Homeland Security warned. (Star Tribune)
The FDA backed down somewhat on contaminated losartan, giving drugmakers 6 months to get rid of NMBA (N-Nitroso-N-methyl-4-aminobutyric acid), to ease shortages. (FiercePharma)
A toilet seat is under development to monitor heart failure via weight, heart rate, stroke volume, and other built-in sensor data. (Cardiovascular Business)
Cardiovascular guidelines haven’t been getting more evidence based, an analysis in JAMA showed. (NPR)
Catheter ablation without electrical mapping of the pulmonary veins “delivers the same outcomes for less cost,” the AVATAR-AF trial showed. (ESCardio.org)
The Galactic-HF trial of novel cardiac myosin activator omecamtiv mecarbil for heart failure got the greenlight to continue unchanged after a planned interim analysis. (The Motley Fool)
The GLP-1 receptor agonist semaglutide (Ozempic) is going for a secondary CV prevention indication in type 2 diabetes, based on the PIONEER and SUSTAIN 6 trials. (AJMC.com)
Cook Medical’s transseptal needle is under a Class I recall due to risk of detached plastic fragments. (Diagnostic and Interventional Cardiology)
The FDA gave premarket approval to the Venovo venous stent for treating obstructions in the iliac and femoral veins. (FDA News)
A video game with myoelectric feedback might help stroke rehabilitation, researchers reported in Neurorehabilitation and Neural Repair.
The Acticor and Rivacor family of high-voltage cardiac rhythm management devices gained FDA approval, Biotronik announced.